Stall-Break Protocol
MOTS-C + Tirzepatide
Dual-Pathway Fat Loss Acceleration · For the GLP-1 Plateau Patient · 9-Week Protocol
Tirzepatide controls the input — appetite and insulin response. MOTS-C controls the engine — mitochondria and AMPK activation. Together they create a two-front metabolic attack that the body cannot adapt to as easily as a single-pathway intervention.
Instant PDF download · Clinical reference document
Why the Combination Works
Two Pathways. One Breakthrough.
Dual-Pathway Fat Burn
GLP-1 reduces caloric input while MOTS-C increases the rate at which fat is oxidized in mitochondria.
AMPK Reactivation
MOTS-C re-sensitizes the AMPK pathway that chronic caloric restriction downregulates, restoring metabolic rate.
Muscle Insulin Sensitivity
MOTS-C drives glucose into skeletal muscle independently of insulin, reducing fat storage signals throughout the body.
The Protocol
Four Phases. Nine Weeks.
Load and Assess
- Continue Tirzepatide on established schedule
- Begin MOTS-C: 5 mg / 3x per week, fasted morning
- Establish baseline: weight, energy, sleep quality, appetite
- Track injection site reactions or unusual fatigue
Increase MOTS-C Frequency
- Advance MOTS-C to 5x per week if tolerating well
- Consider pre-workout dosing on training days
- Monitor: scale trends, body composition, metabolic energy
- Hold Tirzepatide dose unless plateau persists past Week 6
Evaluate and Adjust
- Assess body composition; labs if applicable (glucose, lipids)
- If plateau persists: consider BPC-157 or AOD-9604 adjunct
- If strong response: assess Tirzepatide taper timeline
- Weekly self-report: energy, mood, cravings, sleep
Sustain and Protect
- Cycle MOTS-C to preserve receptor sensitivity
- Begin planning Tirzepatide taper as goal weight approaches
- Introduce long-term metabolic maintenance strategies
Get the Protocol
Instant Digital Access
MOTS-C + Tirzepatide Stall-Break Protocol™
Instant digital download · PDF format · Yours forever
- Full 9-Week Clinical Protocol (PDF)
- Phase-by-Phase Dosing Schedule
- Side-by-Side Mechanism Comparison (Tirzepatide vs MOTS-C)
- Injection Site Rotation Guide
- Monitoring & Checkpoint Tracker
- Hypoglycemia Risk & Safety Notes
- Expected Timeline to Results
- Lifetime access + all future updates
🔒 Secure checkout via Stripe · Instant PDF delivery
This protocol is intended for use under clinical supervision. All dosing decisions should be individualized based on patient history, labs, and provider assessment. This document is a clinical reference tool — not a substitute for clinical guidance. MOTS-C is not FDA-approved as a therapeutic agent.
